The pharmaceutical industry is undergoing a major transformation, placing patients at the forefront of drug development like ...

In conclusion, a demerger, like any major pivot, is a high-stakes, high-value moment where everything matters. Reconnect to ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

Discussing Pfizer's platform, the lawmakers write that it "creates the impression that any patient interested in a particular ...

Pharma companies are moving their Generative AI (GenAI) investments from pilot to production through exploration, ...

Many will celebrate having an extra hour in bed – perhaps forgetting how they lost an hour at the end of March when the ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

The Japanese drugmaker said that interim results from the 530-patient VISIONARY study showed that sibeprenlimab achieved a ...

To learn more about the true value of AI and GenAI in pharma, pharmaphorum spoke with Sudip Chakraborty, Principal and Head ...

In 2018, the EEA accounted for 18% and China made up around 9%, with the massive increase in the latter in a few short years ...